---
	annotation-target: Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf
---



>%%
>```annotation-json
>{"created":"2022-07-23T16:10:51.369Z","updated":"2022-07-23T16:10:51.369Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":4071,"end":4342},{"type":"TextQuoteSelector","exact":"Standard-care second-line treat-ment  in  the  curative  setting  for  patients  with  relapsed  or  refractory  large  B-cell  lymphoma  is  high-dose  chemotherapy  with  au-tologous stem-cell transplantation if the disease is responsive to salvage chemoimmunotherapy.1","prefix":"for  L a rge  B- Cell  Lymphom a","suffix":"-3 Certain disease characteristi"}]}]}
>```
>%%
>*%%PREFIX%%for  L a rge  B- Cell  Lymphom a%%HIGHLIGHT%% ==Standard-care second-line treat-ment  in  the  curative  setting  for  patients  with  relapsed  or  refractory  large  B-cell  lymphoma  is  high-dose  chemotherapy  with  au-tologous stem-cell transplantation if the disease is responsive to salvage chemoimmunotherapy.1== %%POSTFIX%%-3 Certain disease characteristi*
>%%LINK%%[[#^4ou16fx5dh4|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^4ou16fx5dh4


>%%
>```annotation-json
>{"created":"2022-07-23T16:11:06.471Z","updated":"2022-07-23T16:11:06.471Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":4637,"end":4859},{"type":"TextQuoteSelector","exact":"Patients whose disease does not respond to salvage chemother-apy  and  those  who  are  not  considered  to  be  candidates  for  high-dose  chemotherapy  with  autologous  stem-cell  transplantation  have  poor  outcomes.","prefix":" the likelihood of response.4,5 ","suffix":"4,6,7  These  patients  may  ben"}]}]}
>```
>%%
>*%%PREFIX%%the likelihood of response.4,5%%HIGHLIGHT%% ==Patients whose disease does not respond to salvage chemother-apy  and  those  who  are  not  considered  to  be  candidates  for  high-dose  chemotherapy  with  autologous  stem-cell  transplantation  have  poor  outcomes.== %%POSTFIX%%4,6,7  These  patients  may  ben*
>%%LINK%%[[#^vnroae3q3k|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^vnroae3q3k


>%%
>```annotation-json
>{"created":"2022-07-23T16:12:12.443Z","updated":"2022-07-23T16:12:12.443Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":4967,"end":5234},{"type":"TextQuoteSelector","exact":"The  autologous  anti-CD19  chimeric  antigen  receptor (CAR) T-cell therapy axicabtagene cilo-leucel (axi-cel) is approved for the treatment of patients with relapsed or refractory large B-cell lymphoma who have received at least two previ-ous  systemic  therapies.8","prefix":"different mecha-nisms of action.","suffix":",9  In  the  ZUMA-1  trial,  whi"}]}]}
>```
>%%
>*%%PREFIX%%different mecha-nisms of action.%%HIGHLIGHT%% ==The  autologous  anti-CD19  chimeric  antigen  receptor (CAR) T-cell therapy axicabtagene cilo-leucel (axi-cel) is approved for the treatment of patients with relapsed or refractory large B-cell lymphoma who have received at least two previ-ous  systemic  therapies.8== %%POSTFIX%%,9  In  the  ZUMA-1  trial,  whi*
>%%LINK%%[[#^ii1d0p7u3fk|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^ii1d0p7u3fk


>%%
>```annotation-json
>{"created":"2022-07-23T16:17:03.726Z","updated":"2022-07-23T16:17:03.726Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":7744,"end":7820},{"type":"TextQuoteSelector","exact":"Randomization was stratified according to response  to  first-line  therapy ","prefix":"dard-care  chemoimmunother-apy. ","suffix":" (refractory  vs.  re-lapsed dis"}]}]}
>```
>%%
>*%%PREFIX%%dard-care  chemoimmunother-apy.%%HIGHLIGHT%% ==Randomization was stratified according to response  to  first-line  therapy== %%POSTFIX%%(refractory  vs.  re-lapsed dis*
>%%LINK%%[[#^8ikhztd5aia|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^8ikhztd5aia


>%%
>```annotation-json
>{"created":"2022-07-23T16:17:12.820Z","updated":"2022-07-23T16:17:12.820Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":7858,"end":7894},{"type":"TextQuoteSelector","exact":"and the second-line age-adjusted IPI","prefix":"actory  vs.  re-lapsed disease) ","suffix":" (0 or 1 risk factor [indicating"}]}]}
>```
>%%
>*%%PREFIX%%actory  vs.  re-lapsed disease)%%HIGHLIGHT%% ==and the second-line age-adjusted IPI== %%POSTFIX%%(0 or 1 risk factor [indicating*
>%%LINK%%[[#^54ldqwwuglg|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^54ldqwwuglg


>%%
>```annotation-json
>{"created":"2022-07-23T16:21:21.354Z","text":"Procedimento que separa células brancas do resto do sangue, sem tirar o resto do sangue do paciente.","updated":"2022-07-23T16:21:21.354Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":8004,"end":8063},{"type":"TextQuoteSelector","exact":"Patients  in  the  axi-cel  group  underwent  leukapheresis","prefix":"ctors [indicating high risk]).  ","suffix":", followed by conditioning chemo"}]}]}
>```
>%%
>*%%PREFIX%%ctors [indicating high risk]).%%HIGHLIGHT%% ==Patients  in  the  axi-cel  group  underwent  leukapheresis== %%POSTFIX%%, followed by conditioning chemo*
>%%LINK%%[[#^3zjdpgi72va|show annotation]]
>%%COMMENT%%
>Procedimento que separa células brancas do resto do sangue, sem tirar o resto do sangue do paciente.
>%%TAGS%%
>#Técnica
^3zjdpgi72va


>%%
>```annotation-json
>{"created":"2022-07-24T01:12:58.212Z","text":"Teve dias anteriores a contagem com quimioterapia","updated":"2022-07-24T01:12:58.212Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":8065,"end":8387},{"type":"TextQuoteSelector","exact":"followed by conditioning chemo-therapy  with  cyclophosphamide  (at  a  dose  of  500  mg  per  square  meter  of  body-surface  area  per day) and fludarabine (30 mg per square meter per day) at −5, −4, and −3 days before receiving a single infusion of axi-cel (target dose, 2×106 CAR T cells per kilogram of body weight)","prefix":"roup  underwent  leukapheresis, ","suffix":". Op-tional bridging therapy was"}]}]}
>```
>%%
>*%%PREFIX%%roup  underwent  leukapheresis,%%HIGHLIGHT%% ==followed by conditioning chemo-therapy  with  cyclophosphamide  (at  a  dose  of  500  mg  per  square  meter  of  body-surface  area  per day) and fludarabine (30 mg per square meter per day) at −5, −4, and −3 days before receiving a single infusion of axi-cel (target dose, 2×106 CAR T cells per kilogram of body weight)== %%POSTFIX%%. Op-tional bridging therapy was*
>%%LINK%%[[#^9m2elg2f4g|show annotation]]
>%%COMMENT%%
>Teve dias anteriores a contagem com quimioterapia
>%%TAGS%%
>
^9m2elg2f4g


>%%
>```annotation-json
>{"created":"2022-07-24T01:15:05.762Z","updated":"2022-07-24T01:15:05.762Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":8454,"end":8600},{"type":"TextQuoteSelector","exact":"Patients in the standard-care group received two or three cycles of protocol-defined, investigator-selected,  platinum-based  chemoim-munotherapy.","prefix":"mited to glucocor-ticoids only. ","suffix":"  Patients  who  had  a  complet"}]}]}
>```
>%%
>*%%PREFIX%%mited to glucocor-ticoids only.%%HIGHLIGHT%% ==Patients in the standard-care group received two or three cycles of protocol-defined, investigator-selected,  platinum-based  chemoim-munotherapy.== %%POSTFIX%%Patients  who  had  a  complet*
>%%LINK%%[[#^3t9pkn99udr|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^3t9pkn99udr


>%%
>```annotation-json
>{"created":"2022-07-24T01:22:35.281Z","text":"Síndrome de liberação de [[Citocina|citocinas]] é uma síndrome inflamatória aguda sistêmica que causa febre e disfunção múltipla de órgãos (comum em leucemia linfoblástica aguda de células B).","updated":"2022-07-24T01:22:35.281Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":9461,"end":9488},{"type":"TextQuoteSelector","exact":"cytokine  release  syndrome","prefix":"UMA-1.13 The severity  of  the  ","suffix":"  was  graded according to the m"}]}]}
>```
>%%
>*%%PREFIX%%UMA-1.13 The severity  of  the%%HIGHLIGHT%% ==cytokine  release  syndrome== %%POSTFIX%%was  graded according to the m*
>%%LINK%%[[#^2l633zko7u4|show annotation]]
>%%COMMENT%%
>Síndrome de liberação de [[Citocina|citocinas]] é uma síndrome inflamatória aguda sistêmica que causa febre e disfunção múltipla de órgãos (comum em leucemia linfoblástica aguda de células B).
>%%TAGS%%
>#Importante
^2l633zko7u4


>%%
>```annotation-json
>{"created":"2022-07-24T03:56:31.988Z","text":"Período que não houveram eventos na progressão da doença de alguma maneira (termina quando há)","updated":"2022-07-24T03:56:31.988Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":9848,"end":9868},{"type":"TextQuoteSelector","exact":"event-free  survival","prefix":"sThe  primary  end  point  was  ","suffix":"  (defined as the time from rand"}]}]}
>```
>%%
>*%%PREFIX%%sThe  primary  end  point  was%%HIGHLIGHT%% ==event-free  survival== %%POSTFIX%%(defined as the time from rand*
>%%LINK%%[[#^xcig2p6cdq|show annotation]]
>%%COMMENT%%
>Período que não houveram eventos na progressão da doença de alguma maneira (termina quando há)
>%%TAGS%%
>
^xcig2p6cdq


>%%
>```annotation-json
>{"created":"2022-07-24T03:59:03.425Z","updated":"2022-07-24T03:59:03.425Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":10560,"end":10616},{"type":"TextQuoteSelector","exact":"Exploratory  end  points included blood CAR T-cell level","prefix":"ncidence  of  adverse  events.  ","suffix":"s (in the axi-cel group). Diseas"}]}]}
>```
>%%
>*%%PREFIX%%ncidence  of  adverse  events.%%HIGHLIGHT%% ==Exploratory  end  points included blood CAR T-cell level== %%POSTFIX%%s (in the axi-cel group). Diseas*
>%%LINK%%[[#^pkuobxjdo1f|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^pkuobxjdo1f



>%%
>```annotation-json
>{"created":"2022-07-24T04:09:46.465Z","updated":"2022-07-24T04:09:46.465Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":15170,"end":15352},{"type":"TextQuoteSelector","exact":"Among the patients in the axi-cel group, 178 (99%)  underwent  leukapheresis  and  170  (94%)  received axi-cel; 65 patients (36%) received bridg-ing  therapy  with  glucocorticoids.","prefix":" in the Supplementary Appendix).","suffix":"  Axi-cel  was  successfully  ma"}]}]}
>```
>%%
>*%%PREFIX%%in the Supplementary Appendix).%%HIGHLIGHT%% ==Among the patients in the axi-cel group, 178 (99%)  underwent  leukapheresis  and  170  (94%)  received axi-cel; 65 patients (36%) received bridg-ing  therapy  with  glucocorticoids.== %%POSTFIX%%Axi-cel  was  successfully  ma*
>%%LINK%%[[#^rmn1cffmc0k|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^rmn1cffmc0k




>%%
>```annotation-json
>{"created":"2022-07-24T04:10:49.169Z","updated":"2022-07-24T04:10:49.169Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":15354,"end":15452},{"type":"TextQuoteSelector","exact":"Axi-cel  was  successfully  manufactured  for  all  the  patients  who  underwent  leukapheresis  ","prefix":"herapy  with  glucocorticoids.  ","suffix":"(see  the  Supple-mentary  Resul"}]}]}
>```
>%%
>*%%PREFIX%%herapy  with  glucocorticoids.%%HIGHLIGHT%% ==Axi-cel  was  successfully  manufactured  for  all  the  patients  who  underwent  leukapheresis== %%POSTFIX%%(see  the  Supple-mentary  Resul*
>%%LINK%%[[#^cutk3soz1zn|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^cutk3soz1zn


>%%
>```annotation-json
>{"created":"2022-07-24T04:11:28.441Z","updated":"2022-07-24T04:11:28.441Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":15713,"end":15930},{"type":"TextQuoteSelector","exact":"Among the  patients  in  the  standard-care  group,  168  (94%)  received  platinum-based  salvage  chemo-therapy,  and  64  (36%)  received  high-dose  che-motherapy and underwent autologous stem-cell transplantation","prefix":" the investigator) was 13 days. ","suffix":" (including 2 patients who under"}]}]}
>```
>%%
>*%%PREFIX%%the investigator) was 13 days.%%HIGHLIGHT%% ==Among the  patients  in  the  standard-care  group,  168  (94%)  received  platinum-based  salvage  chemo-therapy,  and  64  (36%)  received  high-dose  che-motherapy and underwent autologous stem-cell transplantation== %%POSTFIX%%(including 2 patients who under*
>%%LINK%%[[#^aq52qva4wf|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^aq52qva4wf


>%%
>```annotation-json
>{"created":"2022-07-24T04:16:14.669Z","updated":"2022-07-24T04:16:14.669Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":16521,"end":16621},{"type":"TextQuoteSelector","exact":"The  event-free  survival  curves  show  that  treat-ment with axi-cel was superior to standard care","prefix":"standard-care group (Table S4). ","suffix":" (hazard  ratio  for  event  or "}]}]}
>```
>%%
>*%%PREFIX%%standard-care group (Table S4).%%HIGHLIGHT%% ==The  event-free  survival  curves  show  that  treat-ment with axi-cel was superior to standard care== %%POSTFIX%%(hazard  ratio  for  event  or*
>%%LINK%%[[#^nbkar5ds7b|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^nbkar5ds7b


>%%
>```annotation-json
>{"created":"2022-07-24T04:16:26.617Z","updated":"2022-07-24T04:16:26.617Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":16707,"end":16843},{"type":"TextQuoteSelector","exact":"The  improvements  in  event-free survival with axi-cel as compared with standard care were consistent in all prespecified key subgroups","prefix":"I,  0.31  to  0.51;  P<0.001).  ","suffix":" (Fig. 2B).The percentage of pat"}]}]}
>```
>%%
>*%%PREFIX%%I,  0.31  to  0.51;  P<0.001).%%HIGHLIGHT%% ==The  improvements  in  event-free survival with axi-cel as compared with standard care were consistent in all prespecified key subgroups== %%POSTFIX%%(Fig. 2B).The percentage of pat*
>%%LINK%%[[#^vm9mn83eos|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^vm9mn83eos


>%%
>```annotation-json
>{"created":"2022-07-24T04:19:23.719Z","updated":"2022-07-24T04:19:23.719Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":17615,"end":17843},{"type":"TextQuoteSelector","exact":"Overall, 72 patients (40%) in the axi-cel group and 81 (45%) in the standard-care group died from any cause; 52 patients (29%) in  the  axi-cel  group  and  65  (36%)  in  the  stan-dard-care group died from progressive disease.","prefix":"  in  the  standard-care group. ","suffix":"A total of 56% of the patients i"}]}]}
>```
>%%
>*%%PREFIX%%in  the  standard-care group.%%HIGHLIGHT%% ==Overall, 72 patients (40%) in the axi-cel group and 81 (45%) in the standard-care group died from any cause; 52 patients (29%) in  the  axi-cel  group  and  65  (36%)  in  the  stan-dard-care group died from progressive disease.== %%POSTFIX%%A total of 56% of the patients i*
>%%LINK%%[[#^t3z7rmgvk3e|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^t3z7rmgvk3e


>%%
>```annotation-json
>{"created":"2022-07-24T04:22:06.684Z","updated":"2022-07-24T04:22:06.684Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":18500,"end":18790},{"type":"TextQuoteSelector","exact":"The  median  progression-free  survival  was  14.7  months  (95%  CI,  5.4  to  could  not  be  esti-mated)  in  the  axi-cel  group  and  3.7  months  (95% CI, 2.9 to 5.3) in the standard-care group (hazard  ratio  for  progression  or  death,  0.49;  95%  CI,  0.37  to  0.65)  (Fig.  3B)","prefix":"95% CI, 0.46 to 1.05) (Fig. S3).","suffix":".  The  estimated  progression-f"}]}]}
>```
>%%
>*%%PREFIX%%95% CI, 0.46 to 1.05) (Fig. S3).%%HIGHLIGHT%% ==The  median  progression-free  survival  was  14.7  months  (95%  CI,  5.4  to  could  not  be  esti-mated)  in  the  axi-cel  group  and  3.7  months  (95% CI, 2.9 to 5.3) in the standard-care group (hazard  ratio  for  progression  or  death,  0.49;  95%  CI,  0.37  to  0.65)  (Fig.  3B)== %%POSTFIX%%.  The  estimated  progression-f*
>%%LINK%%[[#^g8iivgkmul|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^g8iivgkmul


>%%
>```annotation-json
>{"created":"2022-07-24T04:22:39.119Z","updated":"2022-07-24T04:22:39.119Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":19020,"end":19190},{"type":"TextQuoteSelector","exact":"Adverse  events  of  grade  3  or  higher  occurred  in  155  of  170  patients  (91%)  who  re-ceived axi-cel and in 140 of 168 patients (83%) who received standard care","prefix":"e adverse event of any  grade.  ","suffix":". The most commonly reported adv"}]}]}
>```
>%%
>*%%PREFIX%%e adverse event of any  grade.%%HIGHLIGHT%% ==Adverse  events  of  grade  3  or  higher  occurred  in  155  of  170  patients  (91%)  who  re-ceived axi-cel and in 140 of 168 patients (83%) who received standard care== %%POSTFIX%%. The most commonly reported adv*
>%%LINK%%[[#^mmpa3g2m7f|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^mmpa3g2m7f


>%%
>```annotation-json
>{"created":"2022-07-24T04:24:10.197Z","text":"Quando o número de células sanguíneas estão anormalmente baixo","updated":"2022-07-24T04:24:10.197Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":21948,"end":21959},{"type":"TextQuoteSelector","exact":" cytopenias","prefix":"respectively.The  frequency  of ","suffix":"  is  summarized  in  Table  2. "}]}]}
>```
>%%
>*%%PREFIX%%respectively.The  frequency  of%%HIGHLIGHT%% ==cytopenias== %%POSTFIX%%is  summarized  in  Table  2.*
>%%LINK%%[[#^jof5wi2oifn|show annotation]]
>%%COMMENT%%
>Quando o número de células sanguíneas estão anormalmente baixo
>%%TAGS%%
>
^jof5wi2oifn


>%%
>```annotation-json
>{"created":"2022-07-24T04:27:10.849Z","updated":"2022-07-24T04:27:10.849Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":22427,"end":22556},{"type":"TextQuoteSelector","exact":"No  cases  of  replica-tion-competent  retrovirus  infection  or  axi-cel  treatment–related  secondary  cancer  were  re-ported.","prefix":" transplantation  (Table  S6).  ","suffix":"  Hypogammaglobulinemia  during "}]}]}
>```
>%%
>*%%PREFIX%%transplantation  (Table  S6).%%HIGHLIGHT%% ==No  cases  of  replica-tion-competent  retrovirus  infection  or  axi-cel  treatment–related  secondary  cancer  were  re-ported.== %%POSTFIX%%Hypogammaglobulinemia  during*
>%%LINK%%[[#^muq3su54fb|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^muq3su54fb


>%%
>```annotation-json
>{"created":"2022-07-24T04:27:59.100Z","text":"Baixos níveis séricos de anticorpos","updated":"2022-07-24T04:27:59.100Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":22558,"end":22579},{"type":"TextQuoteSelector","exact":"Hypogammaglobulinemia","prefix":"dary  cancer  were  re-ported.  ","suffix":"  during  treat-ment  occurred  "}]}]}
>```
>%%
>*%%PREFIX%%dary  cancer  were  re-ported.%%HIGHLIGHT%% ==Hypogammaglobulinemia== %%POSTFIX%%during  treat-ment  occurred*
>%%LINK%%[[#^wqc7ohz7cu|show annotation]]
>%%COMMENT%%
>Baixos níveis séricos de anticorpos
>%%TAGS%%
>
^wqc7ohz7cu


>%%
>```annotation-json
>{"created":"2022-07-24T04:29:51.428Z","updated":"2022-07-24T04:29:51.428Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":23078,"end":23499},{"type":"TextQuoteSelector","exact":"Fatal  adverse  events  occurred  in  7  patients  (4%)  in  the  axi-cel  cohort  (of  which  only  one  event [hepatitis B virus reactivation] was consid-ered by the investigators to be related to axi-cel) and in 2 patients (1%) in the standard-care co-hort (both events [cardiac arrest and acute respi-ratory distress syndrome] were considered by the investigators to be related to high-dose chemo-therapy) (Table S9).","prefix":" Supplementary  Results section.","suffix":"Cytokine  release  syndrome  occ"}]}]}
>```
>%%
>*%%PREFIX%%Supplementary  Results section.%%HIGHLIGHT%% ==Fatal  adverse  events  occurred  in  7  patients  (4%)  in  the  axi-cel  cohort  (of  which  only  one  event [hepatitis B virus reactivation] was consid-ered by the investigators to be related to axi-cel) and in 2 patients (1%) in the standard-care co-hort (both events [cardiac arrest and acute respi-ratory distress syndrome] were considered by the investigators to be related to high-dose chemo-therapy) (Table S9).== %%POSTFIX%%Cytokine  release  syndrome  occ*
>%%LINK%%[[#^4ha0hbw8rz5|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^4ha0hbw8rz5


>%%
>```annotation-json
>{"created":"2022-07-24T04:30:22.113Z","updated":"2022-07-24T04:30:22.113Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":23667,"end":23722},{"type":"TextQuoteSelector","exact":"No deaths related to cytokine release syndrome occurred","prefix":" occurring in 11 patients (6%). ","suffix":". In the safety popula-tion,  to"}]}]}
>```
>%%
>*%%PREFIX%%occurring in 11 patients (6%).%%HIGHLIGHT%% ==No deaths related to cytokine release syndrome occurred== %%POSTFIX%%. In the safety popula-tion,  to*
>%%LINK%%[[#^blc4k8v9u86|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^blc4k8v9u86


>%%
>```annotation-json
>{"created":"2022-07-24T04:36:47.759Z","updated":"2022-07-24T04:36:47.759Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":34244,"end":34436},{"type":"TextQuoteSelector","exact":"The median time to peak CAR T-cell levels was 7 days (range, 2 to 233) after the axi-cel infusion (Table S10 and Fig. S5). The median peak CAR T-cell level was 25.84 cells per cubic millimeter","prefix":"1 paresthesia. CAR T-Cell Levels","suffix":", Standard Care BetterAxi-cel Be"}]}]}
>```
>%%
>*%%PREFIX%%1 paresthesia. CAR T-Cell Levels%%HIGHLIGHT%% ==The median time to peak CAR T-cell levels was 7 days (range, 2 to 233) after the axi-cel infusion (Table S10 and Fig. S5). The median peak CAR T-cell level was 25.84 cells per cubic millimeter== %%POSTFIX%%, Standard Care BetterAxi-cel Be*
>%%LINK%%[[#^5hc14s63vmg|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^5hc14s63vmg


>%%
>```annotation-json
>{"created":"2022-07-24T04:38:36.905Z","updated":"2022-07-24T04:38:36.905Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":36817,"end":36874},{"type":"TextQuoteSelector","exact":" No occurrences of anti–axi-cel antibodies were confirmed","prefix":"observed  in the ZUMA-1 study.18","suffix":".D i s c u s s i o n The prognos"}]}]}
>```
>%%
>*%%PREFIX%%observed  in the ZUMA-1 study.18%%HIGHLIGHT%% ==No occurrences of anti–axi-cel antibodies were confirmed== %%POSTFIX%%.D i s c u s s i o n The prognos*
>%%LINK%%[[#^iio0ogna4or|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^iio0ogna4or


>%%
>```annotation-json
>{"text":"Existem pessoas que não respondem a quimioimunoterapia, e fatores relacionados a idade podem diminuir a resposta a ela.","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":36895,"end":37164},{"type":"TextQuoteSelector","exact":"The prognosis for patients with relapsed or re-fractory large B-cell lymphoma after the receipt of  first-line  therapy  remains  poor,  with  most  patients unable to receive definitive therapy with high-dose  chemotherapy  and  autologous  stem-cell  transplantation.","prefix":"e confirmed.D i s c u s s i o n","suffix":"4,6,7  In  this  international,"}]}],"created":"2022-07-24T04:39:32.758Z","updated":"2022-07-24T04:39:32.758Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}
>```
>%%
>*%%PREFIX%%e confirmed.D i s c u s s i o n%%HIGHLIGHT%% ==The prognosis for patients with relapsed or re-fractory large B-cell lymphoma after the receipt of  first-line  therapy  remains  poor,  with  most  patients unable to receive definitive therapy with high-dose  chemotherapy  and  autologous  stem-cell  transplantation.== %%POSTFIX%%4,6,7  In  this  international,*
>%%LINK%%[[#^f4xfhz50bvj|show annotation]]
>%%COMMENT%%
>Existem pessoas que não respondem a quimioimunoterapia, e fatores relacionados a idade podem diminuir a resposta a ela.
>%%TAGS%%
>
^f4xfhz50bvj


>%%
>```annotation-json
>{"created":"2022-07-24T04:40:04.525Z","updated":"2022-07-24T04:40:04.525Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":37371,"end":37404},{"type":"TextQuoteSelector","exact":"clear  improvement  with  axi-cel","prefix":"l  lym-phoma,  we  observed  a  ","suffix":",  as  compared  with  standard "}]}]}
>```
>%%
>*%%PREFIX%%l  lym-phoma,  we  observed  a%%HIGHLIGHT%% ==clear  improvement  with  axi-cel== %%POSTFIX%%,  as  compared  with  standard*
>%%LINK%%[[#^dn5in13seom|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^dn5in13seom


>%%
>```annotation-json
>{"created":"2022-07-24T04:40:14.421Z","updated":"2022-07-24T04:40:14.421Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":37448,"end":37517},{"type":"TextQuoteSelector","exact":"event-free survival and the percentage of patients with  a  response.","prefix":"red  with  standard  care,  in  ","suffix":"  Event-free  survival  is  a  w"}]}]}
>```
>%%
>*%%PREFIX%%red  with  standard  care,  in%%HIGHLIGHT%% ==event-free survival and the percentage of patients with  a  response.== %%POSTFIX%%Event-free  survival  is  a  w*
>%%LINK%%[[#^osdxkn6hq3|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^osdxkn6hq3


>%%
>```annotation-json
>{"created":"2022-07-24T04:41:38.252Z","updated":"2022-07-24T04:41:38.252Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":37519,"end":37670},{"type":"TextQuoteSelector","exact":"Event-free  survival  is  a  widely  accepted,  robust  early  efficacy  end  point  in  clinical trials involving patients with large B-cell lymphoma,","prefix":"of patients with  a  response.  ","suffix":"  on  the  basis  of  retrospect"}]}]}
>```
>%%
>*%%PREFIX%%of patients with  a  response.%%HIGHLIGHT%% ==Event-free  survival  is  a  widely  accepted,  robust  early  efficacy  end  point  in  clinical trials involving patients with large B-cell lymphoma,== %%POSTFIX%%on  the  basis  of  retrospect*
>%%LINK%%[[#^4ky9pc7dwim|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^4ky9pc7dwim


>%%
>```annotation-json
>{"created":"2022-07-24T04:42:40.083Z","updated":"2022-07-24T04:42:40.083Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":37848,"end":38114},{"type":"TextQuoteSelector","exact":" Patients  with  relapsed  or  refractory  large  B-cell  lymphoma  who do not have a response to salvage chemo-therapy  (i.e.,  who  have  progressive  or  stable  disease) will not benefit from high-dose chemo-therapy  with  autologous  stem-cell  transplanta-tion","prefix":"l  and  overall  survival.19-21 ","suffix":".22  In  this  scenario,  a  cha"}]}]}
>```
>%%
>*%%PREFIX%%l  and  overall  survival.19-21%%HIGHLIGHT%% ==Patients  with  relapsed  or  refractory  large  B-cell  lymphoma  who do not have a response to salvage chemo-therapy  (i.e.,  who  have  progressive  or  stable  disease) will not benefit from high-dose chemo-therapy  with  autologous  stem-cell  transplanta-tion== %%POSTFIX%%.22  In  this  scenario,  a  cha*
>%%LINK%%[[#^km1no6ay26f|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^km1no6ay26f


>%%
>```annotation-json
>{"created":"2022-07-24T04:56:07.428Z","updated":"2022-07-24T04:56:07.428Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":38342,"end":38537},{"type":"TextQuoteSelector","exact":"Axi-cel therapy was superior to standard care with a median event-free survival that was longer by a factor of more than 4, a 2-year event-free survival  that  was  higher  by  a  factor  of  2.5","prefix":"ortant end point for this trial.","suffix":",  a  significantly higher perce"}]}]}
>```
>%%
>*%%PREFIX%%ortant end point for this trial.%%HIGHLIGHT%% ==Axi-cel therapy was superior to standard care with a median event-free survival that was longer by a factor of more than 4, a 2-year event-free survival  that  was  higher  by  a  factor  of  2.5== %%POSTFIX%%,  a  significantly higher perce*
>%%LINK%%[[#^by9ybsu3aig|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^by9ybsu3aig


>%%
>```annotation-json
>{"created":"2022-07-24T04:56:45.362Z","updated":"2022-07-24T04:56:45.362Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":38677,"end":38940},{"type":"TextQuoteSelector","exact":"vent-free sur-vival  outcomes  with  standard  care  in  this  trial  were  consistent  with  those  that  have  been  ob-served  in  patients  with  refractory  or  early  re-lapsed  disease  who  were  receiving  second-line  therapy in the post-rituximab era.4","prefix":"ents with a complete response. E","suffix":",6,7 Treatment with axi-cel also"}]}]}
>```
>%%
>*%%PREFIX%%ents with a complete response. E%%HIGHLIGHT%% ==vent-free sur-vival  outcomes  with  standard  care  in  this  trial  were  consistent  with  those  that  have  been  ob-served  in  patients  with  refractory  or  early  re-lapsed  disease  who  were  receiving  second-line  therapy in the post-rituximab era.4== %%POSTFIX%%,6,7 Treatment with axi-cel also*
>%%LINK%%[[#^rxray2dxni|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^rxray2dxni


>%%
>```annotation-json
>{"created":"2022-07-24T04:57:09.352Z","updated":"2022-07-24T04:57:09.352Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":38961,"end":39051},{"type":"TextQuoteSelector","exact":"xi-cel also led to longer event-free survival than  standard  care  across  key  subgroups","prefix":"ximab era.4,6,7 Treatment with a","suffix":",  in-cluding patients with high"}]}]}
>```
>%%
>*%%PREFIX%%ximab era.4,6,7 Treatment with a%%HIGHLIGHT%% ==xi-cel also led to longer event-free survival than  standard  care  across  key  subgroups== %%POSTFIX%%,  in-cluding patients with high*
>%%LINK%%[[#^emg9bkb7htu|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^emg9bkb7htu


>%%
>```annotation-json
>{"created":"2022-07-24T04:57:48.261Z","updated":"2022-07-24T04:57:48.261Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":39215,"end":39277},{"type":"TextQuoteSelector","exact":"although further improvements in these subgroups  are  needed.","prefix":"and an age of 65 years or more, ","suffix":"23  Although  30%  of  the  pati"}]}]}
>```
>%%
>*%%PREFIX%%and an age of 65 years or more,%%HIGHLIGHT%% ==although further improvements in these subgroups  are  needed.== %%POSTFIX%%23  Although  30%  of  the  pati*
>%%LINK%%[[#^6thb511o3p4|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^6thb511o3p4


>%%
>```annotation-json
>{"created":"2022-07-24T04:58:04.028Z","updated":"2022-07-24T04:58:04.028Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":39281,"end":39462},{"type":"TextQuoteSelector","exact":"Although  30%  of  the  patients  in  our  trial  were  65  years  of  age  or  older, elderly patients may not qualify for trans-plantation  in  certain  regions  of  the  world.24","prefix":"hese subgroups  are  needed.23  ","suffix":",25 This trial showed that axi-c"}]}]}
>```
>%%
>*%%PREFIX%%hese subgroups  are  needed.23%%HIGHLIGHT%% ==Although  30%  of  the  patients  in  our  trial  were  65  years  of  age  or  older, elderly patients may not qualify for trans-plantation  in  certain  regions  of  the  world.24== %%POSTFIX%%,25 This trial showed that axi-c*
>%%LINK%%[[#^wyk2z1uf9ml|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^wyk2z1uf9ml


>%%
>```annotation-json
>{"created":"2022-07-24T04:58:54.204Z","updated":"2022-07-24T04:58:54.204Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":39466,"end":39629},{"type":"TextQuoteSelector","exact":"This trial showed that axi-cel can be an effective second-line therapeutic option in elderly patients who do not have clinically significant coexisting conditions.","prefix":"  regions  of  the  world.24,25 ","suffix":"The difference in overall surviv"}]}]}
>```
>%%
>*%%PREFIX%%regions  of  the  world.24,25%%HIGHLIGHT%% ==This trial showed that axi-cel can be an effective second-line therapeutic option in elderly patients who do not have clinically significant coexisting conditions.== %%POSTFIX%%The difference in overall surviv*
>%%LINK%%[[#^2n9p0j2qw1j|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^2n9p0j2qw1j


>%%
>```annotation-json
>{"created":"2022-07-24T04:59:17.262Z","updated":"2022-07-24T04:59:17.262Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":39629,"end":39725},{"type":"TextQuoteSelector","exact":"The difference in overall survival between the two groups did not reach statistical significance","prefix":"gnificant coexisting conditions.","suffix":". Patients who had disease progr"}]}]}
>```
>%%
>*%%PREFIX%%gnificant coexisting conditions.%%HIGHLIGHT%% ==The difference in overall survival between the two groups did not reach statistical significance== %%POSTFIX%%. Patients who had disease progr*
>%%LINK%%[[#^4z3v6et08tq|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^4z3v6et08tq


>%%
>```annotation-json
>{"created":"2022-07-24T05:00:52.073Z","text":"Deve ter comprometido a taxa de sobrevivência geral","updated":"2022-07-24T05:00:52.073Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":42034,"end":42118},{"type":"TextQuoteSelector","exact":"standard-care  group  could  re-ceive  CAR  T-cell  therapy  outside  the  protocol ","prefix":" d i c i n e response  in  the  ","suffix":" (which occurred in 56% of the p"}]}]}
>```
>%%
>*%%PREFIX%%d i c i n e response  in  the%%HIGHLIGHT%% ==standard-care  group  could  re-ceive  CAR  T-cell  therapy  outside  the  protocol== %%POSTFIX%%(which occurred in 56% of the p*
>%%LINK%%[[#^2z7oef5kwes|show annotation]]
>%%COMMENT%%
>Deve ter comprometido a taxa de sobrevivência geral
>%%TAGS%%
>
^2z7oef5kwes


>%%
>```annotation-json
>{"created":"2022-07-24T05:02:11.701Z","updated":"2022-07-24T05:02:11.701Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":42308,"end":42420},{"type":"TextQuoteSelector","exact":"The medi-an overall survival in the standard-care group was longer than has been observed in historical stud-ies","prefix":"sensitivity analyses (Fig. S3). ","suffix":"7,26; this finding is potentiall"}]}]}
>```
>%%
>*%%PREFIX%%sensitivity analyses (Fig. S3).%%HIGHLIGHT%% ==The medi-an overall survival in the standard-care group was longer than has been observed in historical stud-ies== %%POSTFIX%%7,26; this finding is potentiall*
>%%LINK%%[[#^zkhzp6rpxd|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^zkhzp6rpxd


>%%
>```annotation-json
>{"created":"2022-07-24T05:06:11.632Z","updated":"2022-07-24T05:06:11.632Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":42623,"end":43128},{"type":"TextQuoteSelector","exact":"Although nearly all the patients who had been randomly assigned to the axi-cel group received an infusion of axi-cel, only a minority of patients (36%) in the standard-care group received high-dose  chemotherapy  with  autologous  stem-cell  transplantation;  this  percentage  is  consistent  with  findings  in  historical  studies,  especially  those  with  high  proportions  of  patients  with  primary refractory disease and early relapse and of  patients  who  had  received  rituximab  previ-ously","prefix":"apses after second-line therapy.","suffix":" (Table S11).4,7,26 Given that i"}]}]}
>```
>%%
>*%%PREFIX%%apses after second-line therapy.%%HIGHLIGHT%% ==Although nearly all the patients who had been randomly assigned to the axi-cel group received an infusion of axi-cel, only a minority of patients (36%) in the standard-care group received high-dose  chemotherapy  with  autologous  stem-cell  transplantation;  this  percentage  is  consistent  with  findings  in  historical  studies,  especially  those  with  high  proportions  of  patients  with  primary refractory disease and early relapse and of  patients  who  had  received  rituximab  previ-ously== %%POSTFIX%%(Table S11).4,7,26 Given that i*
>%%LINK%%[[#^kd5zl1p72go|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^kd5zl1p72go


>%%
>```annotation-json
>{"created":"2022-07-24T05:06:59.506Z","updated":"2022-07-24T05:06:59.506Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":44774,"end":44982},{"type":"TextQuoteSelector","exact":"because  the  majority  of  patients  do  not  receive  definitive  therapy  with  high-dose  chemotherapy  and  autologous  stem-cell transplantation, outcomes with the current standard-care therapy are poor","prefix":"ymphom asalvage  therapy,  and  ","suffix":". By design, the ZUMA-7  trial  "}]}]}
>```
>%%
>*%%PREFIX%%ymphom asalvage  therapy,  and%%HIGHLIGHT%% ==because  the  majority  of  patients  do  not  receive  definitive  therapy  with  high-dose  chemotherapy  and  autologous  stem-cell transplantation, outcomes with the current standard-care therapy are poor== %%POSTFIX%%. By design, the ZUMA-7  trial*
>%%LINK%%[[#^mrh1lwp0tj9|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^mrh1lwp0tj9


>%%
>```annotation-json
>{"created":"2022-07-24T05:07:50.404Z","updated":"2022-07-24T05:07:50.404Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":44999,"end":45277},{"type":"TextQuoteSelector","exact":"ZUMA-7  trial  randomly  assigned  patients  to  groups  before  the  receipt  of  salvage  chemoim-munotherapy and showed that avoidance of sal-vage  chemoimmunotherapy  and  earlier  use  of  CAR T-cell therapy could result in improvements in event-free survival and response.","prefix":"herapy are poor. By design, the ","suffix":"The  adverse-event  profile  of "}]}]}
>```
>%%
>*%%PREFIX%%herapy are poor. By design, the%%HIGHLIGHT%% ==ZUMA-7  trial  randomly  assigned  patients  to  groups  before  the  receipt  of  salvage  chemoim-munotherapy and showed that avoidance of sal-vage  chemoimmunotherapy  and  earlier  use  of  CAR T-cell therapy could result in improvements in event-free survival and response.== %%POSTFIX%%The  adverse-event  profile  of*
>%%LINK%%[[#^7m2j0sbjxxe|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^7m2j0sbjxxe


>%%
>```annotation-json
>{"created":"2022-07-24T05:11:08.452Z","updated":"2022-07-24T05:11:08.452Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":45475,"end":45813},{"type":"TextQuoteSelector","exact":"The  frequency  of  adverse  events,  including  those  of  grade 3 or higher and of serious adverse events, was high in the two treatment groups, although the  adverse-event  profile  differed  between  the  two  groups,  with  the  incidence  of  cytokine  re-lease  syndrome  and  neurologic  events  being  higher in the axi-cel group","prefix":" large  B-cell  lymphoma.13,27  ","suffix":".In this trial, bridging therapy"}]}]}
>```
>%%
>*%%PREFIX%%large  B-cell  lymphoma.13,27%%HIGHLIGHT%% ==The  frequency  of  adverse  events,  including  those  of  grade 3 or higher and of serious adverse events, was high in the two treatment groups, although the  adverse-event  profile  differed  between  the  two  groups,  with  the  incidence  of  cytokine  re-lease  syndrome  and  neurologic  events  being  higher in the axi-cel group== %%POSTFIX%%.In this trial, bridging therapy*
>%%LINK%%[[#^e9785dxrtfr|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^e9785dxrtfr


>%%
>```annotation-json
>{"created":"2022-07-24T05:12:39.042Z","updated":"2022-07-24T05:12:39.042Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":45829,"end":46048},{"type":"TextQuoteSelector","exact":"bridging therapy was restricted to glucocorticoids to avoid the progression of lym-phoma  during  the  axi-cel  manufacturing  pro-cess  and  to  isolate  the  effects  of  CAR  T-cell  therapy  as  second-line  therapy","prefix":"he axi-cel group.In this trial, ","suffix":".  Although  this  approach  pot"}]}]}
>```
>%%
>*%%PREFIX%%he axi-cel group.In this trial,%%HIGHLIGHT%% ==bridging therapy was restricted to glucocorticoids to avoid the progression of lym-phoma  during  the  axi-cel  manufacturing  pro-cess  and  to  isolate  the  effects  of  CAR  T-cell  therapy  as  second-line  therapy== %%POSTFIX%%.  Although  this  approach  pot*
>%%LINK%%[[#^di68ajydiba|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^di68ajydiba


>%%
>```annotation-json
>{"created":"2022-07-24T05:14:17.841Z","updated":"2022-07-24T05:14:17.841Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":46283,"end":46472},{"type":"TextQuoteSelector","exact":"Prohibition of the use of chemotherapy bridging, which could alone result in 40 to 50% of patients having a response,4,7,26 ensured that the results in the axi-cel group were not confounded","prefix":"  primary  refractory  disease. ","suffix":". In the real world, however, br"}]}]}
>```
>%%
>*%%PREFIX%%primary  refractory  disease.%%HIGHLIGHT%% ==Prohibition of the use of chemotherapy bridging, which could alone result in 40 to 50% of patients having a response,4,7,26 ensured that the results in the axi-cel group were not confounded== %%POSTFIX%%. In the real world, however, br*
>%%LINK%%[[#^99f8fe93uhb|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^99f8fe93uhb


>%%
>```annotation-json
>{"created":"2022-07-24T05:14:35.445Z","updated":"2022-07-24T05:14:35.445Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":46493,"end":46566},{"type":"TextQuoteSelector","exact":"however, bridging chemother-apy may sometimes need to be started urgently","prefix":" confounded. In the real world, ","suffix":".In patients who received and ha"}]}]}
>```
>%%
>*%%PREFIX%%confounded. In the real world,%%HIGHLIGHT%% ==however, bridging chemother-apy may sometimes need to be started urgently== %%POSTFIX%%.In patients who received and ha*
>%%LINK%%[[#^hrfrcxbrdeh|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^hrfrcxbrdeh



>%%
>```annotation-json
>{"created":"2022-07-24T05:16:00.891Z","updated":"2022-07-24T05:16:00.891Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":46771,"end":46843},{"type":"TextQuoteSelector","exact":"Although the duration of re-sponse was numerically favorable for axi-cel","prefix":"n,  outcomes  were not as poor. ","suffix":", the 95% confidence interval wa"}]}]}
>```
>%%
>*%%PREFIX%%n,  outcomes  were not as poor.%%HIGHLIGHT%% ==Although the duration of re-sponse was numerically favorable for axi-cel== %%POSTFIX%%, the 95% confidence interval wa*
>%%LINK%%[[#^79h031s4ywp|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^79h031s4ywp


>%%
>```annotation-json
>{"created":"2022-07-24T05:16:51.358Z","updated":"2022-07-24T05:16:51.358Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":46968,"end":47395},{"type":"TextQuoteSelector","exact":"because  chemosensitivity  is  un-known  before  the  initiation  of  treatment,  the  use of  axi-cel as second-line therapy may avoid  additional chemotherapy in patients who would ultimately not receive a transplant, may shorten the  time  to  definitive  therapy,  and  may  avoid  both  the  risk  of  clinical  deterioration  and  the  potential effect on CAR T-cell fitness with more numerous previous lines of therapy.2","prefix":"ct  (Fig.  S4).  Nevertheless,  ","suffix":"8Not  all  patients  benefited  "}]}]}
>```
>%%
>*%%PREFIX%%ct  (Fig.  S4).  Nevertheless,%%HIGHLIGHT%% ==because  chemosensitivity  is  un-known  before  the  initiation  of  treatment,  the  use of  axi-cel as second-line therapy may avoid  additional chemotherapy in patients who would ultimately not receive a transplant, may shorten the  time  to  definitive  therapy,  and  may  avoid  both  the  risk  of  clinical  deterioration  and  the  potential effect on CAR T-cell fitness with more numerous previous lines of therapy.2== %%POSTFIX%%8Not  all  patients  benefited*
>%%LINK%%[[#^amhpljah8ga|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^amhpljah8ga


>%%
>```annotation-json
>{"created":"2022-07-24T05:17:00.535Z","updated":"2022-07-24T05:17:00.535Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":47396,"end":47465},{"type":"TextQuoteSelector","exact":"Not  all  patients  benefited  from  axi-cel  as  second-line therapy","prefix":"ous previous lines of therapy.28","suffix":". The ZUMA-7 trial has some limi"}]}]}
>```
>%%
>*%%PREFIX%%ous previous lines of therapy.28%%HIGHLIGHT%% ==Not  all  patients  benefited  from  axi-cel  as  second-line therapy== %%POSTFIX%%. The ZUMA-7 trial has some limi*
>%%LINK%%[[#^jm8dwstro9b|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^jm8dwstro9b


>%%
>```annotation-json
>{"created":"2022-07-24T05:17:34.616Z","updated":"2022-07-24T05:17:34.616Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":47471,"end":47584},{"type":"TextQuoteSelector","exact":"ZUMA-7 trial has some limitations, including the lack of examination of CD19  expression  on  progressive  tumors","prefix":"l  as  second-line therapy. The ","suffix":",  deter-mination  of  whether  "}]}]}
>```
>%%
>*%%PREFIX%%l  as  second-line therapy. The%%HIGHLIGHT%% ==ZUMA-7 trial has some limitations, including the lack of examination of CD19  expression  on  progressive  tumors== %%POSTFIX%%,  deter-mination  of  whether*
>%%LINK%%[[#^7zbdz0s7kic|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^7zbdz0s7kic


>%%
>```annotation-json
>{"created":"2022-07-24T05:19:11.208Z","updated":"2022-07-24T05:19:11.208Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":47820,"end":47948},{"type":"TextQuoteSelector","exact":"  Additional  correlative  analyses are necessary to determine markers of response  durability  and  mechanisms  of  resis-tance","prefix":"or  size  or  inflammation.29-31","suffix":".  Given  that  it  remains  unc"}]}]}
>```
>%%
>*%%PREFIX%%or  size  or  inflammation.29-31%%HIGHLIGHT%% ==Additional  correlative  analyses are necessary to determine markers of response  durability  and  mechanisms  of  resis-tance== %%POSTFIX%%.  Given  that  it  remains  unc*
>%%LINK%%[[#^aupcwhmdtp|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^aupcwhmdtp


>%%
>```annotation-json
>{"created":"2022-07-24T05:20:09.474Z","updated":"2022-07-24T05:20:09.474Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":48408,"end":48561},{"type":"TextQuoteSelector","exact":"4 this trial did not en-roll patients with large B-cell lymphoma relapse that  occurred  more  than  12  months  after  the  receipt of induction therapy","prefix":"y in the post-rituximab era,33,3","suffix":". Relapses occurring later after"}]}]}
>```
>%%
>*%%PREFIX%%y in the post-rituximab era,33,3%%HIGHLIGHT%% ==4 this trial did not en-roll patients with large B-cell lymphoma relapse that  occurred  more  than  12  months  after  the  receipt of induction therapy== %%POSTFIX%%. Relapses occurring later after*
>%%LINK%%[[#^s0xgiqd60ho|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^s0xgiqd60ho


>%%
>```annotation-json
>{"created":"2022-07-24T05:24:13.571Z","updated":"2022-07-24T05:24:13.571Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":49248,"end":49496},{"type":"TextQuoteSelector","exact":"Treatment with axi-cel induced high-grade adverse events in the vast majority of pa-tients,  but  few  patients  had  fatal  effects  from  treatment and the magnitude of the toxicity was consistent  with  previous  reports  in  third-line  therapy","prefix":"fractory large B-cell lymphoma. ","suffix":",  although  unique  problems  a"}]}]}
>```
>%%
>*%%PREFIX%%fractory large B-cell lymphoma.%%HIGHLIGHT%% ==Treatment with axi-cel induced high-grade adverse events in the vast majority of pa-tients,  but  few  patients  had  fatal  effects  from  treatment and the magnitude of the toxicity was consistent  with  previous  reports  in  third-line  therapy== %%POSTFIX%%,  although  unique  problems  a*
>%%LINK%%[[#^vdy252on14m|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^vdy252on14m


>%%
>```annotation-json
>{"created":"2022-07-24T18:28:07.075Z","updated":"2022-07-24T18:28:07.075Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":10241,"end":10303},{"type":"TextQuoteSelector","exact":"Key secondary end points were response  and  overall  survival","prefix":"ing to blind-ed central review. ","suffix":".  Secondary  end  points includ"}]}]}
>```
>%%
>*%%PREFIX%%ing to blind-ed central review.%%HIGHLIGHT%% ==Key secondary end points were response  and  overall  survival== %%POSTFIX%%.  Secondary  end  points includ*
>%%LINK%%[[#^wp1wsk0kr2r|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^wp1wsk0kr2r
